Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world spesolimab study in Chinese adults with generalized pustular psoriasis
ChiCTR2400089387Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on ChiCTR2400089387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089387.